Back to article: Neutralizing the threat: harnessing broadly neutralizing antibodies against HIV-1 for treatment and prevention
FIGURE 2: Sites of vulnerability on an HIV-1 envelope spike. BnAbs can be directed against several epitopes on gp120 including the CD4bs, the V1/V2 apex, the V3 glycan supersite site, and the silent face as well as epitopes on gp41 such as the gp41-gp120 interface region, the fusion peptide and the MPER. Examples of bnAbs targeting these sites are shown in Table 1.